SOPHiA GENETICS SA filings document the disclosures of a foreign private issuer that reports through Form 6-K and related registration statements. The company’s filings include unaudited interim condensed consolidated financial statements, management discussion and analysis, press releases on operating results, and Swiss annual report materials tied to its AI-driven precision medicine software business.
Other filings cover annual general meeting notices, proxy materials, shareholder voting documents, incorporation by reference into Form F-3 and Form S-8 registration statements, and capital-structure matters such as credit-agreement amendments, term loan commitments, warrants, and ordinary-share purchase rights.
SOPHiA GENETICS SA Chief Executive Officer Camblong Jurgi has filed a Form 3 reporting his initial ownership in the company. He directly holds 3,307,325 ordinary shares, including 616,351 ordinary shares issuable upon settlement of restricted stock units that vest over time, and 891,320 ordinary shares have been pledged under lending arrangements. He also reports several share options giving rights to buy additional ordinary shares at exercise prices ranging from 3.1600 to 18.0000 per share, with expirations between late 2028 and early 2035. Certain option and RSU awards vest in scheduled monthly or quarterly installments through 2028.
SOPHiA GENETICS SA filed an initial ownership report for Chief Scientific Officer Xu Zhenyu, detailing his existing equity position. He directly holds 537,724 ordinary shares, including 115,002 shares issuable under restricted stock units that vest over time, and 147,840 shares that have been pledged under lending arrangements. He also holds multiple share options over ordinary shares with expirations ranging from 2027 to 2035; some options are already fully vested, while others vest in monthly or quarterly installments through dates specified in the footnotes. The filing lists these holdings and does not show any new purchases or sales.
SOPHiA GENETICS SA Chief Technology Officer Abhimanyu Verma filed an initial Form 3 reporting his equity holdings in the company. He directly holds 125,813 ordinary shares, which include 80,762 ordinary shares issuable upon settlement of four restricted stock unit grants that vest over time through dates extending to April 2, 2028.
Verma also holds several share options over ordinary shares: 31,847 at an exercise price of $8.36 expiring March 30, 2032, 130,112 at $4.72 expiring April 3, 2033, 182,927 at $4.96 expiring April 2, 2034, and 136,364 at $3.29 expiring April 2, 2035. These options vest in stages, with portions becoming exercisable on specific dates and the remainder vesting in equal monthly installments through 2027.
SOPHiA GENETICS SA Chief Financial Officer George Cardoza filed an initial ownership report showing his equity position in the company. He holds 185,632 Ordinary Shares directly. He also holds share options over 183,333 Ordinary Shares at an exercise price of $3.4000 per share, expiring on December 18, 2034, and separate share options over 187,500 Ordinary Shares at an exercise price of $3.2900 per share, expiring on April 2, 2035. Footnotes state that 70,826 additional Ordinary Shares are issuable upon settlement of restricted stock units, vesting over time subject to his continued service.
SOPHiA GENETICS SA Chief Medical Officer Philippe Menu filed an initial ownership report showing direct holdings of 174,224 ordinary shares. This figure includes 115,002 ordinary shares issuable upon settlement of four restricted stock unit grants that vest over time, subject to continued service. He also reports several share option awards over ordinary shares with various exercise prices and expirations between 2030 and 2035, providing additional potential equity exposure if exercised in the future.
SOPHiA GENETICS SA President Ross Muken filed an initial Form 3 reporting his equity holdings in the company. The filing shows multiple share option grants over ordinary shares with exercise prices ranging from $3.29 to $18.00 and expiration dates between 2031 and 2035.
The report also lists direct ownership of 273,093 ordinary shares, which includes 249,158 ordinary shares issuable upon settlement of five RSU grants that vest in installments through dates extending to 2028. In addition, 200,000 ordinary shares are held indirectly by the Ross Muken 2026 Irrevocable Trust, for which Muken disclaims beneficial ownership except for any pecuniary interest.
SOPHiA GENETICS SA Chief People Officer Manuela Valente filed an initial statement of beneficial ownership. She reports direct ownership of 152,759 ordinary shares, including 67,994 ordinary shares issuable upon settlement of four restricted stock unit grants that vest over time, subject to continued service.
Valente also reports several share option awards over ordinary shares with exercise prices ranging from 3.2000 to 18.0000 per share and expiration dates between 2029 and 2035. These options cover underlying blocks of 10,000, 20,000, 47,170, 92,937, 160,061 and 119,318 ordinary shares, reflecting her equity-based compensation position rather than new market transactions.
SOPHiA GENETICS SA director Troy Cox has filed an initial ownership report showing a substantial equity position in the company. He directly holds 309,019 ordinary shares, which include 33,784 ordinary shares to be delivered under a restricted share unit award that vests in full at the issuer’s next annual shareholder meeting, subject to his continued service.
He also holds several share option awards over ordinary shares. These include options over 11,500 shares at an exercise price of 4.0100 per share expiring on June 19, 2029, 162,740 shares at 4.1200 per share expiring on January 1, 2030, and 49,751 shares at 3.0400 per share expiring on June 18, 2035. The filing states that the share options are fully vested and exercisable.
SOPH reports multiple Rule 10b5-1 sales by Jurgi Camblong. The filing lists numerous planned sales of Common stock executed under a 10b5-1 plan between 12/19/2025 and 03/13/2026, including 95,488 shares on 01/09/2026 (amount 491,626.46) and 37,299 shares on 01/22/2026 (amount 209,917.83).